Medical News

December 5 2003–Prostate cancer is the most common male malignancy in Western countries. Wider use of screening and changes in treatment practice will force companies to adapt their products and marketing goals. These changes will occur over the next five years, but manufacturers must implement new business plans now to capitalize on the effects of stage migration at diagnosis and new treatment approaches.

Scope

Quantitative treatment data from over 440 physicians: 60 from Japan, France, Germany, Italy, Spain and the UK, and 80 from the US

Qualitative feedback on key findings and future trends in the treatment of prostate cancer and the management of disease and treatment side effects

Coverage of the hot topics affecting current treatment patterns, from the impact of IMRT on brachytherapy to the increasing use of bisphosphonates

A strong future focus on key issues, including the increasing use of third generation cytotoxics in HRPC and the implementation of screening in Europe

Report Highlights

AstraZeneca is promoting Casodex monotherapy heavily in non-metastatic disease as an alternative to an LHRH agonist. Approval for Casodex monotherapy has been delayed in some markets, but physicians are already prescribing off-label, especially in patients with dementia, a condition that can be exacerbated by the use of LHRH agonists.

In Japan the volume usage of hormonal drug therapy is far more common as the average age of the patient is well over 70 and so curative treatment is often contraindicated. Datamonitor believes the high volume usage of hormonal therapies makes this an important country in which to market effective, low toxicity drugs.

Clinical trials have shown the lack of activity of estramustine in hormone refractory prostate cancer, but the drug is still commonly used because of the lack of alternatives. Recent trial results of estramustine in combination with Aventis? Taxotere show much greater efficacy and usage of this combination is already significant.

This report is designed to:

Identify hot topics and key issues for practicing prostate cancer specialists ? the questions they really want answered

Predict future trends in the treatment of prostate cancer and how to capitalize on forthcoming changes in treatment practice

Plan product development to fill prostate cancer market niches as defined by practicing physicians

For a complete index of this report click on http://www.researchandmarkets.com/reports/41482

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com

December 5 2003–Prostate cancer is the most common male malignancy in Western countries. Wider use of screening and changes in treatment practice will force companies to adapt their products and marketing goals. These changes will occur over the next five years, but manufacturers must implement new business plans now to capitalize on the effects of stage migration at diagnosis and new treatment approaches.

Scope

Quantitative treatment data from over 440 physicians: 60 from Japan, France, Germany, Italy, Spain and the UK, and 80 from the US

Qualitative feedback on key findings and future trends in the treatment of prostate cancer and the management of disease and treatment side effects

Coverage of the hot topics affecting current treatment patterns, from the impact of IMRT on brachytherapy to the increasing use of bisphosphonates

A strong future focus on key issues, including the increasing use of third generation cytotoxics in HRPC and the implementation of screening in Europe

Report Highlights

AstraZeneca is promoting Casodex monotherapy heavily in non-metastatic disease as an alternative to an LHRH agonist. Approval for Casodex monotherapy has been delayed in some markets, but physicians are already prescribing off-label, especially in patients with dementia, a condition that can be exacerbated by the use of LHRH agonists.

In Japan the volume usage of hormonal drug therapy is far more common as the average age of the patient is well over 70 and so curative treatment is often contraindicated. Datamonitor believes the high volume usage of hormonal therapies makes this an important country in which to market effective, low toxicity drugs.

Clinical trials have shown the lack of activity of estramustine in hormone refractory prostate cancer, but the drug is still commonly used because of the lack of alternatives. Recent trial results of estramustine in combination with Aventis? Taxotere show much greater efficacy and usage of this combination is already significant.

This report is designed to:

Identify hot topics and key issues for practicing prostate cancer specialists ? the questions they really want answered

Predict future trends in the treatment of prostate cancer and how to capitalize on forthcoming changes in treatment practice

Plan product development to fill prostate cancer market niches as defined by practicing physicians

For a complete index of this report click on http://www.researchandmarkets.com/reports/41482

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com